Data gathered: November 27
AI Stock Analysis - Astria Therapeutics (ATXS)
Analysis generated September 26, 2024. Powered by Chat GPT.
Astria Therapeutics is a biopharmaceutical company dedicated to creating new medicines for rare, debilitating diseases. The company focuses heavily on research and development activities aimed at addressing unmet medical needs. Astria competes in a niche market but is primarily driven by its core competency in innovative treatments and its ability to bring new products to market through clinical trials and regulatory approvals.
Stock Alerts - Astria Therapeutics (ATXS)
 |
Astria Therapeutics | November 20 Price is down by -5.3% in the last 24h. |
|
Astria Therapeutics | November 19 Price is up by 5% in the last 24h. |
|
Astria Therapeutics | November 18 Price is down by -5% in the last 24h. |
|
Astria Therapeutics | November 15 Price is down by -5.1% in the last 24h. |
Alternative Data for Astria Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,255 | Sign up | Sign up | Sign up |
| Twitter Mentions | 33 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Astria Therapeutics
None
| Price | $10.50 |
| Target Price | Sign up |
| Volume | 110,500 |
| Market Cap | $564M |
| Year Range | $8.83 - $15.99 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of “Buy” by BrokeragesNovember 24 - ETF Daily News |
 |
Astria Therapeutics’ (ATXS) “Buy” Rating Reaffirmed at HC WainwrightNovember 17 - ETF Daily News |
|
Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 at OppenheimerNovember 16 - ETF Daily News |
 |
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 13 - Yahoo |
 |
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare ConferenceNovember 12 - Yahoo |
 |
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 4 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 8.5M | -8.5M | -25M | 0 | -0.420 |
| Q2 '24 | 0 | 8.1M | -8.1M | -24M | -29M | -0.430 |
| Q1 '24 | 0 | 8.4M | -8.4M | -20M | -24M | -0.380 |
| Q4 '23 | 0 | 7.3M | -7.3M | -31M | -19M | -0.940 |
| Q3 '23 | 0 | 6.9M | -6.9M | -18M | -20M | -0.630 |
Insider Transactions View All
| EDELMAN JOSEPH filed to buy 4,873,721 shares at $12.1. February 5 '24 |
| EDELMAN JOSEPH filed to buy 2,392,371 shares at $6.2. December 22 '23 |
Similar companies
Read more about Astria Therapeutics (ATXS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Astria Therapeutics?
The Market Cap of Astria Therapeutics is $564M.
What is the current stock price of Astria Therapeutics?
Currently, the price of one share of Astria Therapeutics stock is $10.50.
How can I analyze the ATXS stock price chart for investment decisions?
The ATXS stock price chart above provides a comprehensive visual representation of Astria Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Astria Therapeutics shares. Our platform offers an up-to-date ATXS stock price chart, along with technical data analysis and alternative data insights.
Does ATXS offer dividends to its shareholders?
As of our latest update, Astria Therapeutics (ATXS) does not offer dividends to its shareholders. Investors interested in Astria Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Astria Therapeutics?
Some of the similar stocks of Astria Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.